Daré Bioscience has announced the publication of Phase 1/2 clinical study results for its investigational formulation, DARE-VVA1. The tamoxifen-based product is designed to treat vulvovaginal atrophy (VVA) in women without hormones and was found to be safe and well-tolerated in postmenopausal participants with moderate to severe VVA. Daré is developing DARE-VVA1 as a hormone-free option for patients treated for hormone-receptor positive breast cancer who experience VVA, as estrogen products are often contraindicated for this population. The company plans to submit an Investigational New Drug application and initiate a Phase 2 clinical study of DARE-VVA1. This could be an important therapeutic option for the treatment of VVA, which affects many postmenopausal women and those with a history of HR+ breast cancer. Tamoxifen has unique properties that produce different effects in different types of tissues, making it a promising alternative to traditional estrogen-based therapies.